Last reviewed · How we verify
Nithiocyamine (AMOSCANATE)
Nithiocyamine (generic name: AMOSCANATE) is a drug. It is currently in Phase 2 development.
Nithiocyamine works by binding to specific biological molecules to produce its therapeutic effect.
Nithiocyamine, also known as AMOSCANATE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce its therapeutic effect. Further information on its mechanism of action, safety considerations, and availability is not available. More research is needed to fully understand this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AMOSCANATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a city with many different buildings. Nithiocyamine is like a key that fits into a specific lock on one of those buildings, allowing it to send a signal that helps to treat a particular condition. This is a simplified way of describing how small molecules like Nithiocyamine work.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nithiocyamine CI brief — competitive landscape report
- Nithiocyamine updates RSS · CI watch RSS
Frequently asked questions about Nithiocyamine
What is Nithiocyamine?
How does Nithiocyamine work?
What is the generic name of Nithiocyamine?
What development phase is Nithiocyamine in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing